Health Care/Hospital
PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium
Presentation to highlight the initial safety profile and antitumor activity of PT0253 in advanced solid tumors, including in patients who received prior (K)RAS-targeted therapy BURLINGTON, Mass., Nov. 3, 2026 /PRNewswire/ -- PAQ Therapeutics, a clinical-stage biotechnology company developing tar...
2026-11-03 20:00
2175
Differentia Bio Advances Human Digital Twins with AI-Driven Disease Modeling and Clinical Validation
From millions of molecular measurements to clinically supported therapeutic predictions, Differentia is building AI-powered disease environments for pharmaceutical R&D. SAN FRANCISCO, Nov. 3, 2026 /PRNewswire/ -- Differentia Bio, a developer of AI-powered human disease digital twins, today annou...
2026-11-03 18:48
1712
140th Canton Fair Phase 3 Highlights Intelligent Healthcare Innovations for a Better Life
GUANGZHOU, China, Nov. 3, 2026 /PRNewswire/ -- Phase 3 of the 140th Canton Fair, held from October 31 to November 4, centers on the theme "Better Life." As health remains central to high quality of life, the Intelligent Healthcare Zone has emerged as a focal point for buyers seeking solutions tha...
2026-11-03 14:29
3298
POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements
GUANGZHOU, China, Nov. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on October 28, 2026, it received two letter...
2026-11-03 05:05
2428
Momcozy Introduces Its First-Ever Dual-Motor Double Electric Breast Pump with the Launch of the V3
Building on its leadership in wearable breast pumps, Momcozy expands into primary pumping with smart dual-motor technology, independent suction control, and hands-free milk collection NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Momcozy, a global leader in maternal innovation, today announced the laun...
2026-11-02 22:30
3105
Jin Medical Showcases Innovation Across Four Global Industry Expos: Lightweight Rehabilitation Assistive Line Draws Broad Market Attention
Marking its 20th anniversary, the company completes a four-stop market tour across the Yangtze River Delta, Beijing-Tianjin-Hebei, ASEAN, and Europe, steadily advancing its global footprint. CHANGZHOU, China, Nov. 2, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical...
2026-11-02 22:20
4968
Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
BEIJING, Nov. 2, 2026 /PRNewswire/ -- Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsible for discovery efforts and A...
2026-11-02 22:00
2655
Neurophet and RapidAI Partner to Expand Access to Alzheimer's and MS Treatment Monitoring
- Agreement expands Neurophet's reach into U.S. health systems and builds on RapidAI's leadership in enterprise clinical AI and neurosciences SEOUL, South Korea, Nov. 2, 2026 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, ...
2026-11-02 22:00
2644
Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer
* Trial initiated at Fudan University Shanghai Cancer Center (FUSCC) under the leadership of Leading Principal Investigator Professor Ding-Wei Ye, uniting 11 premier urologic oncology centers across China * Phase II study incorporates a safety run-in phase with a subsequent multi-cohort desig...
2026-11-02 21:25
2327
InventisBio Announces Topline Results of a Phase III Study of Nomelcitinib (TYK2 Inhibitor), Demonstrating Promising Efficacy and Safety in Patients with Moderate to Severe Plaque Psoriasis.
SHANGHAI, Nov. 2, 2026 /PRNewswire/ -- InventisBio Co., Ltd. today announced that itsJH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key secondary endpoint in a registrational Phase III clinical trial for the treatment of moderate-to-severe plaque psor...
2026-11-02 19:00
3556
Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.
SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma")announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfullycompleted patient ...
2026-10-31 13:00
7063
Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"
BOSTON, Oct. 30, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. J...
2026-10-31 00:00
4871
aphranel® Hosts European Physicians in China for Clinical Exchange
Week-Long Programme Under The Norns' Weave Examines Chinese Clinical Practice and Its Potential Applications in Europe SHANGHAI, Oct. 30, 2026 /PRNewswire/ -- aphranel®, the regenerative aesthetics brand of MOYOM Biotech, has launched a clinical exchange programme bringing European physicians to...
2026-10-30 17:00
3303
Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation
Preliminary responses observed in 6 of 8 evaluable urothelial carcinoma patients (75%), including patients previously treated with enfortumab vedotin and pembrolizumab Early antitumor activity also observed in squamous NSCLC, SCLC and prostate cancer SHANGHAI and HANGZHOU, China, Oct. 29, 2026 ...
2026-10-30 09:00
4388
Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or "Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-acting precisionbispecific antibodies for immunology and inflammation, today announced the pricing of ...
2026-10-30 08:15
6849
Yuyu Pharma Explores Animal Health as a New Pathway for Human Drug Innovation
SEOUL, South Korea, Oct. 29, 2026 /PRNewswire/ -- Yuyu Pharma (KRX: 000220) CEO Robert Wonsang Yu shared the company's vision for connecting human and animal health at BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), highlighting how pharmaceutical research and development can create new opportunities ac...
2026-10-29 21:00
3551
Health In Tech to Announce Third Quarter 2026 Financial Results on November 12, 2026
STUART, Fla., Oct. 29, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced that it will release financial results for the third quarter ended September 30, 2026, following the close of market on Thursday, November 12, 2026. Health In ...
2026-10-29 18:30
6054
United Imaging Healthcare Reports 19.43% Revenue Growth in First Nine Months of 2026, with Cumulative R&D Investment Exceeding RMB 10 Billion Since 2022
SHANGHAI, Oct. 29, 2026 /PRNewswire/ -- United Imaging Healthcare (688271.SH), a global innovator in advanced medical imaging technologies and intelligent healthcare solutions, reported revenue of RMB 10.58 billion for the first nine months of 2026, up 19.43% year-on-year. Sustained investment in...
2026-10-29 15:32
4109
United Imaging Healthcare Reports 19.43% Revenue Growth in Q1-Q3 2026, with International Revenue Up 50.30%
SHANGHAI, Oct. 29, 2026 /PRNewswire/ -- United Imaging Healthcare (688271.SH), a global innovator in advanced medical imaging technologies and intelligent healthcare solutions, announced its financial results for the first nine months of 2026, reporting revenue of RMB 10.58 billion, up 19.43% yea...
2026-10-29 15:29
3423
IMDA and NUH Partner in First Open Innovation Platform Collaboration in Public Healthcare
Partnership accelerates healthcare innovation by connecting real-world hospital needs with technology expertise SINGAPORE, Oct. 28, 2026 /PRNewswire/ -- The Infocomm Media Development Authority (IMDA) and the National University Hospital (NUH), through its Kent Ridge Office of Innovation (KROI),...
2026-10-28 17:04
2515
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1168 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1129 media titles]
2026-11-05 06:52Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
[Picked up by 1067 media titles]
2026-11-04 07:31
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
59917
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
55153
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
52974
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
22439
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
17777